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ABSTRACT 
 
Avian pathogenic Escherichia coli (APEC) is an extra-intestinal pathogenic E. coli 
(ExPEC) pathotype that causes avian colibacillosis, resulting in a major economic loss to the 
poultry industry annually.  It’s not known to directly cause disease in humans, however 
APEC is able to transmit its plasmid-encoded virulence genes to human ExPEC pathotypes 
(UPEC and NMEC) or commensal microorganisms present in the human GI tract.  This 
could potentially result in the creation of more virulent or antibiotic resistant strains and 
classifies APEC as potentially zoonotic.  Increased regulation of antibiotic usage as growth 
promoters and disease preventatives in food animals has resulted in a push towards antibiotic 
alternatives.  Original XPCTM (Diamond V, Cedar Rapids) is a Saccharomyces cerevisiae 
fermentation product that has proved efficacious as a growth promoter and in reducing 
different pathogens across numerous animal species.  Ceca from poultry provided a diet with 
this feed additive were collected at the time of slaughter, reconstituted in Luria Broth, plated 
on Xylose Lysine Deoxycholate selective and differential media, and E. coli colonies were 
assayed for the presence of APEC and subjected to an antibiogram.  The presence of APEC 
in each cecum was determined utilizing a pentaplex PCR and individual E. coli isolates were 
tested for resistance against three antibiotics: ceftiofur, enrofloxacin, and chloramphenicol.  
Results revealed an overall reduction in both APEC prevalence and antibiotic resistance, 
supporting XPC as a useful alternative to antibiotics in the poultry industry. 
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CHAPTER 1: GENERAL INTRODUCTION 
 
Thesis Introduction 
Avian pathogenic Escherichia coli (APEC) is the leading cause of avian colibacillosis 
globally and is a major economic burden on the poultry industry due to the morbidity and 
mortality rates.  APEC is classified as an extra-intestinal pathogenic E. coli (ExPEC) along 
with uropathogenic E. coli (UPEC) and neonatal meningitis E. coli (NMEC), the pathotypes 
known to cause disease in humans and mammals.  Each ExPEC pathotype is known to cause 
a distinct disease depending on the location within the host, however they all have a common 
set of virulence genes located primarily on a colicin plasmid.  Over recent years, these 
virulence genes have become associated with antibiotic resistance genes at an alarming 
frequency due to high recombination rates.  Within the poultry industry this is a problem 
because it has increased the challenge of attempting to eliminate APEC from poultry flocks. 
APEC is also gaining further interest as a public health concern due to its ability to reside in 
the gastrointestinal tract of poultry as a commensal organism.  The organism could 
potentially be consumed by the human population and act as a reservoir for virulence and 
resistance genes that can be transferred to other bacterial organisms within the human GI 
tract.  
Given the importance of APEC in both the poultry industry and public health, it is 
imperative to find a method to control its prevalence in the poultry population to reduce 
disease and transference.  The rapid increase in antibiotic resistance across most bacterial 
pathogens means this control method needs to be an alternative to antibiotics.  This study 
focused on Original XPCTM (Diamond V, Cedar Rapids), a Saccharomyces cerevisiae 
2 
 
fermentation product, that has proven efficacious in the reduction of gastrointestinal 
pathogens in numerous animal species.   
This study aims to determine if XPC could be used as a prophylactic treatment for 
APEC in poultry.  If successful it would reduce the morbidity and mortality rates seen in 
poultry, saving the industry millions of dollars.  Additionally, it would mitigate the 
propagation of APEC and its virulence and antibiotic resistance genes.  This could be 
important from a public health perspective to reduce the potential of creating more resistant 
human-associated Enterobacteriaceae pathogens capable of extra-intestinal infection.  To 
accomplish the study goal, poultry fed a diet including XPCTM were tested for the prevalence 
of APEC and antibiotic resistance of E. coli isolated from the cecum. 
Thesis Organization 
 This thesis is organized into four chapters.  Chapter 1 serves as the general 
introduction while Chapter 2 serves as the literature review covering topics relevant to the 
study of ExPEC.  Topics covered in the literature review include a general introduction to 
ExPEC, colicin-encoding plasmids, antibiotic resistance, zoonotic potential of APEC, and 
alternatives to antibiotics.  Chapter 3 is the original research chapter for the study testing the 
effects of Original XPC on APEC prevalence and antibiotic resistance of E. coli colonies 
isolated from poultry cecum.  Chapter 4 includes general discussion, conclusions, and future 
directions.   
The author’s role in this study included assisting in development of the study design 
and culturing of E. coli from poultry cecum, collecting E. coli isolates for later assays, 
performing the laboratory assays, data collection and analysis, and manuscript writing.  
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CHAPTER 2: LITERATURE REVIEW ON EXTRAINTESTINAL PATHOGENIC 
ESCHERICHIA COLI 
 
Escherichia coli (E. coli) is a member of the Enterobacteriaceae family and is 
commonly found in the environment, foods, and gastrointestinal tract of animals and humans 
(1).  Commensal or pathogenic pathotypes are determined by the genome, which consists of a 
core genome and variable mobile genetic elements (2).  The core genome is a conserved set 
of genes encoding the genetic information for essential cellular processes.  Variable mobile 
genetic element is an umbrella term encompassing plasmids, transposons, prophages, and 
mobile genomic islands that encode strain-specific genetic information.  Pathogenic E. coli 
exhibit a variety of pathotypes that are commonly characterized by somatic (O) and flagella 
(H) antigens (3).  Different pathotypes are responsible for different disease syndromes, and 
are most commonly identified by their phenotypic disease characteristics.  Despite their 
different disease presentation all E. coli pathotypes have the same basic scheme of 
pathogenesis; the organism must colonize the mucosal site, evade the host defense systems, 
replicate, and cause cytopathic effect.  This review will focus on pathotypes characterized as 
extra-intestinal pathogenic E. coli (ExPEC), including classification, plasmid carriage, 
antibiotic resistance profile, zoonotic potential, as well as explore current alternatives to 
antibiotics. 
Extra-intestinal Pathogenic E. coli 
Classification of E. coli is important given the large number and variety of strains.  
Phylogenetic grouping is one method used with three assays available; multi-locus enzyme 
electrophoresis, ribotyping, or a triplex PCR assay (4–6).  Four phylogenetic groups have 
been identified for E. coli (A, B1, B2, and D), within which certain pathotype patterns have 
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been observed (7).  These phylogenetic groupings are indicative of a genetic divergence in 
the evolutionary history of E. coli that resulted in group B2 exhibiting more virulent 
tendencies due to the acquisition of virulence genes on plasmids, transposons, genetic 
islands, etc. (8).  Serotyping is also commonly used in the classification of E. coli and is 
based on the 173 O (somatic), 80 K (capsular), and 56 H (flagellar) antigens (9).  
Determination of O and H antigens is by bacterial agglutination, while the K antigens are 
determined primarily by immunoprecipitation in a gel.  The O antigens are based on the 
structure of the polysaccharide side chain present in the lipopolysaccharide in the surface of 
the E. coli, K antigens are related to the structures of acidic polysaccharides on the cell 
surface, and H antigens are related to the proteins that compose the flagella present on the E. 
coli cell.  Numerous serotypes have been identified in the various pathotypes and strains of 
E. coli; some of these serotypes are unique to the pathotype while other serotypes are 
common across multiple pathotypes.   
Many researchers have worked to identify traits to distinguish the three different 
pathotypes of ExPEC; uropathogenic E. coli (UPEC), neonatal meningitis E. coli (NMEC), 
and avian pathogenic E. coli (APEC) (10).  One of the leading causes of urinary tract 
infections (UTIs) is UPEC, typically presenting as a superficial infection of the bladder and 
urinary tract, with about 4% of cases progressing to pyelonephritis (11, 12).  Uncomplicated 
UTIs effect approximately 1 in 3 women by age 24 and cost the United States almost $2 
billion annually (12, 13).  NMEC is the second leading cause of neonatal meningitis globally, 
with a rate of 0.1 cases in every 1000 children born in the industrialized world (14, 15).  
Meningitis typically occurs between 6-9 days of age, has a mortality rate of 20-40%, and of 
those who survive approximately 50% develop neurological problems (15).  Colibacillosis in 
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poultry is primarily a result of APEC infection, causing millions of dollars lost worldwide in 
the poultry industry due to significant morbidity and mortality rates (16, 17).  In the United 
States, at least 30% of commercial flocks are affected by APEC with disease presentation 
ranging from salpingitis, peritonitis, swollen head syndrome, cellulitis, and necrotic 
dermatitis.  While not a known cause of human disease, APEC is important to study as a 
potential human pathogen due to its numerous overlapping virulence characteristics with 
human ExPEC pathotypes.   
Controversy remains as to whether these pathotypes are distinguishable from one 
another.  Johnson et al. (16) identified 5 genes that, when all are present, are indicative of 
APEC, while Logue et al. (18) identified 10 potential discriminators of NMEC.  However, 
there is an overlap of these genes within APEC, UPEC, and NMEC that questions the 
legitimacy of identifying them as individual pathotypes (19–22).  Phylogenetic analysis 
emphasizes this understanding.  The UPEC and NMEC strains most commonly fall into 
groups B2 and D, APEC strains fall into groups A and B2, while commensal strains fall 
primarily into group A (8, 19, 20, 23).  Serotyping analyses indicate NMEC are most 
commonly classified within the O7 and O18 serogroups (20), UPEC within the O1, O2, O6, 
O15, O18, O25, O26, and O75 serogroups (19, 20, 23), and APEC within the O1, O2, O18, 
and O78 serogroups (24–26).  Unfortunately, 10-40% of ExPEC strains are non-typeable, 
therefore serotyping is not a good indication of pathogenicity nor pathotype (19, 20, 23).  The 
molecular analysis of the presence of mobile genetic elements signifies pathogenic potential 
more than broad phylogenic groups. 
 Animal colonization studies support the claim that these may not be unique 
pathotypes after all.  In one study, chicken pulmonary sacs were experimentally infected with 
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UPEC strains and developed lesions similar to APEC.  Further studies include 
experimentally inducing UTI in murine models with APEC, resulting in disease pathology 
associated with UPEC (23).  A study from the same group also found that APEC isolates 
could cause sepsis and neonatal meningitis in a rat model, and that NMEC isolates were 
lethal to chick embryos and caused colisepticemia in chicks (27).  These studies indicate that 
location may be more important for ExPEC than a designated pathotype.  It is important to 
note that while all strains tested caused disease, mortality rates varied depending on the 
strain.   
 Infections caused by ExPEC strains are important to human and animal health, 
resulting in billions of dollars of lost due to health care costs and poultry mortality.  
Phylogenetic analysis and serotyping, although broad also have overlapping commonalities 
across ExPEC, revealing the close similarity of these pathotypes.  This similarity is also 
exemplified in animal infection studies.  As further analysis is done, ExPEC may need to be 
re-evaluated as one path-pathotype rather than three. 
Colicin-Encoding Plasmids 
An important feature of E. coli is the presence of numerous plasmids 
(extrachromosomal genetic elements) that confer different properties to the organism (28).  A 
variety of plasmid sizes have been identified within E. coli with the tendency towards a 
bimodal distribution (fewer copies of large plasmids versus more copies of small plasmids) 
(29).  The large, incompatible plasmids are typically the plasmids that encode virulence or 
resistance genes and are the largest contribution to variation in E. coli pathotypes (30).  
Transfer and recombination of these plasmids is a common occurrence, promoting genetic 
exchange between the genome and plasmids, ultimately leading to a complement of plasmids 
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and extensive genetic variation within individual bacterial chromosomes (31, 32).  Despite 
the variation in genes carried on E. coli plasmids, it has been determined the majority of them 
have a common genetic backbone and therefore likely evolved from a single plasmid (30). 
Invasive extra-intestinal E. coli are most commonly associated with the colicin-
encoding plasmids (33, 34).  Colicins are small molecules, produced by Enterobacteriaceae, 
that are classified as bacteriocins due to their antibacterial activity against related specie of 
bacteria (35).  The ColV plasmid is the most common colicin-encoding plasmid and the 
primary contributor of virulence factors for the three ExPEC pathotypes (36–38).  The 
original understanding of the plasmid purely encoding colicin production has evolved to 
include carriage of numerous virulence-encoding genes that are vital for extra-intestinal 
infection (34).  Insertion sequences flanking the virulent genetic regions indicate that many 
of these traits likely originated in other pathogenic species and were included in the plasmid 
as a result of recombination (39–41).  These molecular events resulted in the acquisition of 
traits such as iron sequestration (39, 42), iron and manganese transportation (43), increased 
serum survival (44), hemagglutination (40), and outer membrane vesicle production (45). 
 Plasmids are a defining feature of Enterobacteriaceae that provide variability in 
pathogenicity and resistance.  Colicin-encoding plasmids harbor the virulence genes that 
define ExPEC strains and are therefore of the utmost importance to study and characterize.  
Identification of these virulence traits allows for elucidation of the detailed pathogenesis, 
which can be used to improve treatment and preventative measures of disease.  
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Molecular Identification of the APEC Pathotype 
The APEC pathotype is conferred through ColV and ColBM plasmids, both encoding 
specific genes that aid in the virulence of the pathogen.  The ColV plasmids are the primary 
plasmids identified as harboring ExPEC virulence traits, with numerous studies indicating the 
importance of this plasmid to the pathogen.  Within the last decade, however a plasmid was 
identified in an APEC strain that also encodes these genes, the ColBM plasmid, which likely 
evolved from ColV (46).  Importantly, the ColBM plasmid can confer antibiotic resistance 
genes as well as virulence genes associated with ColV (47).  This exemplifies the 
prominence that recombination events within the colicin-encoding plasmids can have on the 
pathogenicity of these organisms.  The conserved set of genes, commonly referred to as the 
pathogenicity island, located on the ColV plasmid is important for the successful transfer of 
virulence genes during recombination events (38).  This pathogenicity island has been 
primarily located in APEC and the virulence genes within have been used as genetic 
identifiers for this pathotype (16).  The importance of each virulence gene will now be 
discussed to understand their importance in the pathogenicity of ExPEC.  
Iron is essential for the survival of bacteria due to its contribution to many cellular 
processes, including nucleotide biosynthesis, electron transport, and peroxide reduction (48).  
Mammalian hosts have limited amounts of free iron available as an innate mechanism of 
immunity to pathogenic bacteria through a complex system of proteins meant to sequester 
free iron (49).  In response, pathogenic bacteria developed methods of iron sequestration in 
order to survive and replicate within the host (50).  One common method of acquiring iron in 
deficient host environments is the production of siderophores, which are compounds released 
from the bacteria that competitively bind the iron that is bound by host molecules.  
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Siderophores can then bind to prokaryotic receptors and salvage host iron for use in 
molecular and biochemical processes essential for survival.  The system is not perfect.  For 
example, enteric bacteria produce siderophores referred to as enterochelins, that are inhibited 
by serum albumin, thus useless in systemic infections (51).  To maximize iron salvaging 
capabilities, ExPEC encode different iron sequestration systems both in their genome and on 
plasmids found in APEC pathotypes.  The two iron sequestration systems that have been 
located on the ColV plasmid are the aerobactin and salmochelin operons, which produce 
siderophores that are effective outside of the intestinal tract (30). 
Siderophores produced by the aerobactin operon are hydroxamate compounds that 
have a transient association with the receptors on the bacterial membrane (42).  The 
aerobactin operon region encodes five polypeptides.  Four of the genes (iucABCD) encode 
polypeptides that participate in aerobactin synthesis and one gene (iutA) encodes an outer 
membrane protein that serves as a receptor (52, 53).  Aerobactin has a lower affinity for iron 
compared to enterochelins, requiring it to preferentially scavenge iron from cells and tissues 
(54).  The aerobactin operon is commonly found in most ExPEC, however there are 
variations in its encoded location.  In animal strains, it is more frequently plasmid-encoded 
while in human strains it is most often located on the chromosome (34).  Salmochelins are 
the second type of siderophore commonly found linked to the ColV plasmid and appear to 
contribute more to virulence than aerobactins (39, 55).  The iroA locus is divided into two 
operons, iroBCDE and iroN, and encodes five genes responsible for synthesis, export, and 
import of salmochelins (56).  Salmochelins are glycosylated variants of enterochelins, with 
the modification occuring within the bacteria by IroB and IroE enzymes.  After modification, 
salmochelins are exported from the bacterial cell via the membrane-bound IroC and IroN 
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enzymes.  Upon binding with an iron molecule, the siderophore-iron complex is imported by 
the same membrane enzymes and then degraded by IroD within the bacterial cell.  Despite 
being located on plasmids, both the aerobactin and salmochelin encoding operons are 
regulated by the chromosomally located fur gene product, that represses production of the 
siderophores when efficient amounts of free iron are present in the environment (57, 58). 
Ion transporters encoded on the ColV plasmid are also vital to ExPEC, particularly the 
sitABCD operon, encoding both iron and manganese transporters (43).  The ABC-type 
transporters encoded by this operon have a higher affinity for iron, however the importance 
of manganese import cannot be diminished given its function as an antioxidant as well as a 
detoxifier of radical oxygen species, H2O2 and O2
- (59).  Researchers hypothesize that the use 
of manganese is important because it is a more energy efficient method of protecting the 
bacterial cell from radical oxygen species than superoxide dismutase and peroxidase 
enzymes.  Regulation occurs via the same fur operon as the aerobactin and salmochelin 
operons, which is primarily repressed by iron but also by manganese in some cases (60). 
Commonly coupled with the sit operon is iss, which encodes a polypeptide that 
increases survival of the pathogenic E. coli in host serum (41, 61).  Host serum has numerous 
bactericidal components, the most notable being lysozymes and complement that act on the 
bacterial surface to cause cell lysis (62).  For ExPEC to cause systemic infection, it is 
therefore important to produce a protein able to counteract these serum components.  Three 
variations of iss have been identified; type 1 is primarily located on ColV plasmids and most 
common in APEC and NMEC isolates, while type 3 has primarily been discovered on the 
chromosome of UPEC isolates (41).  Currently nothing is known about the mechanism of the 
gene product, although due to its high homology with a similar chromosomally encoded 
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polypeptide involved in serum survival, it is believed to be a membrane-bound molecule 
(61).  
The final two important virulence genes to briefly identify and discuss are hlyF and 
tsh.  HlyF was originally believed to be a product associated with hemolytic activity (63). 
This characterization was deemed to be inaccurate when studies revealed its involvement in 
the formation of outer membrane vesicles (OMVs) (45).  The OMVs release toxins and 
induce autophagy of eukaryotic cells, an important contribution to the cytopathic effect of 
ExPEC.  The tsh associated with ColV plasmids, encodes a temperature sensitive 
hemagglutinin that has hemagglutination activity on chicken erythrocytes predominately at 
about 26⁰C (40, 64, 65).  Studies done in APEC revealed Tsh may have additional virulence 
contributions, such as acting as an adhesin, increasing the rate of colonization in the airsacs, 
and contributing to lesions and fibrin deposition in the air sacs of poultry (40).  Studies 
evaluating Tsh have primarily been done on APEC, therefore not much is currently known 
about the contribution of Tsh in the virulence of other ExPEC pathotypes.  
The conserved pathogenicity island of the ColV plasmid houses several virulence 
genes crucial to extra-intestinal infections, encoding traits ranging from iron sequestration 
and transportation to serum survival and outer membrane vesicle formation.  The genes 
located on this pathogenicity island have proved useful as predictors of APEC; however, the 
easy transferability of these virulence genes is of great concern. 
Zoonotic Potential of APEC 
Zoonotic organisms, by definition, are organisms that normally reside in animal 
species but can transmit to and infect humans (66).  Controversy exists around the zoonotic 
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potential of APEC pathotypes.  Two arguments are put forward to suggest that APEC should 
be considered a potential concern to human health are that: 1) they are reservoirs for 
promiscuous antibiotic resistance plasmids (67) and 2) the pathotype causes experimental 
disease in multiple hosts (23, 27).  Therefore, the ColV and ColBM plasmids are insidious 
contributors to the zoonotic potential of APEC (30).  The APEC associated plasmid pAPEC-
O2-ColV has been transferred to an avian commensal E. coli and successfully conferred 
pathogenicity within chicken and mice models (68).  Commensal E. coli became lethal to 
chicken embryos upon acquisition of the plasmid and in other studies exhibited enhanced 
growth in human urine, and colonization in the kidney of a murine model (68).  These results 
exemplify the potential of APEC as a zoonotic pathogen for humans, combined with the 
knowledge that APEC can colonize the GI tract of poultry (69).  
Additional evidence for APEC and the colicin plasmids as a public health concern is 
seen in the identification of a plasmid in a Salmonella serovar and drug resistant E. coli 
isolates in avian organic fertilizer (70–72).  Salmonella enterica serovar Kentucky is a 
pathogen that has been increasingly identified as a causative agent of disease in poultry, 
humans, and companion animals; further, it has recently been found to carry the conserved 
pathogenicity island of the ColV plasmid (70, 71).  The carriage of the ColV-like plasmid in 
S. Kentucky has been determined to increase colonization capabilities and virulence of the 
pathogen in extra-intestinal regions in poultry (70).  This plasmid contributes to antibiotic 
resistance through the carriage of tetracycline resistance (71).  Low levels of tetracycline in a 
host or the environment has been shown to increase the occurrence of conjugative transfer of 
tetR encoded plasmids (73).  Given the regular use of antibiotics in animal production (74), 
the dissemination and transfer of the ColV plasmid and its virulence genes is likely being 
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propagated by the industry.  These plasmids are subject to vertical transmission through the 
food chain through the utilization of organic fertilizers from avian compost.  Fertilizers 
produced from organic animal waste are commonly used for vegetable production and 
undergo a composition process thought to reduce the presence of potential microbial 
pathogens found in the avian excrement (75).  Sixty percent of E. coli isolates from fertilizer 
were identified as having at least one gene from the ColV plasmid conserved pathogenicity 
island (72).  Of all the isolates tested, 50% of them were resistant to at least one antibiotic, 
with the most common ones being tetracycline, amoxicillin, ampicillin, and streptomycin.  
This indicates that the composting process is not completely successful at removing E. coli 
encoding APEC virulence and antibiotic resistance genes.  These strains could therefore be 
acquired by humans via consumption and handling of produce.  
 The zoonotic potential of APEC is exemplified by the appearance of pColV virulence 
genes and resistance genes in alternative genera and the environment.  Presence of APEC 
within the GI tract of poultry sent to slaughter is of concern as a source of not only a 
potentially human pathogen, but also a reservoir of virulence and antibiotic resistance genes 
capable of high rates of transmission and recombination.  From a public health stand point, a 
prophylactic treatment needs to be identified to mitigate the transmission of APEC to 
humans. 
Antibiotic Resistance 
 Antibiotic resistance is a problem in pathogenic microorganisms that was first 
identified in the 1930s and is a significant threat to clinical and veterinary health worldwide 
(76).  While development of antibiotic resistance in microorganisms is a natural occurrence 
(77), humans have accelerated the process over the last fifty years due to non-therapeutic an 
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inappropriate therapeutic use of antibiotics (78).  Thus, resulting in upwards of millions of 
metric tons of antibiotics released into the environment (76).  There are many methods in 
which microorganisms can acquire antibiotic resistance genes, but the most concerning is 
plasmid-mediated transmission.  When bacteria are exposed to low levels of antibiotics in 
their environment, an SOS response is activated that enhances plasmid transmission and 
recombination (76, 79).  The continuous use and release of antibiotics in the environment is 
therefore perpetuating the spread of antibiotic resistance genes. 
 Enterobacteriaceae as a family are a reservoir of plasmids bearing antibiotic 
resistance genes undergoing frequent conjugation and transformation (80–82).  Accordingly, 
the high usage of antibiotics in production animals as prophylaxis and growth promoters has 
led to an increase in antibiotic resistance in APEC found in poultry.  Results from data 
demonstrate significantly increased resistance to sulfamethoxazole, tetracycline, 
streptomycin, ampicillin, ciprofloxacin, penicillin, tylosin, and enrofloxacin (24, 83–86).  
Resistance of APEC to many of these drugs has been linked to the acquisition of resistance-
encoding genes, primarily through plasmid recombination (87).  As these mobile genetic 
elements are vertically transmitted through the food chain (88–90), the prodigious use of 
antibiotics in veterinary medicine has significantly contributed to the problem.  
The human clinical impact of this characteristic is far reaching and deeply concerning 
world-wide.  Not only is there significant acquisition of mobile genetic elements from the 
environment and through vertical transmission in the food chain, the misuse of antibiotics in 
clinical settings significantly amplifies this threat.  As of 2010, up to 45% of ExPEC isolates 
from clinical patients were determined to be resistant to cephalosporins, fluoroquinolones, 
and trimethoprim-sulfamethoxazole, all of which are commonly prescribed for Gram 
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negative infections (91).  This increase in resistance within human ExPEC pathotypes is 
likely a result of overprescribing antibiotics for the treatment of uncomplicated urinary tract 
infections (92) and for intrapartum use in females (93). 
 Genotypes conferring resistance pathotypes are diverse.  Many isolates of ExPEC 
have recently been classified as carriers of extended-spectrum β lactamases (ESBLs) which 
provide the pathogen with resistance to a wide variety of β lactams, including 3rd and 4th 
generation cephalosporins and penicillins (94, 95).  Irrespective of host, it has been 
determined that CTX-M is the most prevalent ESBL worldwide (96), and has been identified 
on both narrow and broad host-range plasmids (97).  Strains of E. coli encoded for CTX-M 
hydrolyze penicillins, cephalosporins, and monobactams (98).  Fluoroquinolone resistance is 
also commonly identified in CTX-M encoding isolates due to the presence of closely linked 
plasmid-mediated qnr genes (97).  Additional genes that have been located on a plasmid 
harboring CTX-M encode resistance to aminoglycosides, chloramphenicol, sulfonamide, 
trimethoprim, and tetracycline (99); classifying many CTX-M carrying isolates as multi-drug 
resistant. 
The New Delhi metallo-β-lactamase (NDM-1) is another important β-lactamase that 
has appeared in E. coli within the last decade, enabling resistance to all β-lactams (91, 100).  
NDM-1 has been identified in a UPEC isolate in association with a plasmid belonging to 
sequence type 131 (ST131) (101).  This is an important relationship to understand as more 
than 50% of ST131 clones have been associated with multi-drug resistance in ExPEC and 
almost 70% associated with fluoroquinolone and extended-spectrum cephalosporin resistance 
(102).  Analysis of ST131-positive E. coli has also revealed that they tend to combine both 
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resistance and virulence for increased pathogenesis that was not commonly seen in isolates in 
the past.   
Finally, mcr-1, a colistin resistance-encoding gene, has spread globally within a few 
years (103–106).  Colistin is of the Polymyxin E antibiotic class and is of great concern to 
public health because of its classification as a last resort antibiotic in the treatment of multi-
drug resistant infections (103, 107).  Since its appearance a few years ago, mcr-1 has already 
been identified in ExPEC isolates worldwide (103, 104, 108–110).  The first E. coli 
harboring mcr-1 in the United States was isolated from a patient with a UTI in 2016 (109). 
This colistin resistance gene was located on a novel IncF plasmid that was identified as also 
encoding CTX-M and tetracycline resistance.  The location of these resistance genes on a 
plasmid type well-known for dissemination of genes among Enterobacteriaceae (111) is of 
great concern for public health worldwide. 
Antibiotic resistance has seen dramatic increases in recent decades, largely due to the 
occurrence of resistance genes located on transmissible plasmids.  Inappropriate use of 
antibiotics in feed animals, even at low levels, has escalated the rate of the natural 
transmission process, resulting in the large number of multi-drug resistant pathogens seen 
today.  ExPEC has been associated with plasmids housing genes encoding several ESBLs, 
including CTX-M, NDM-1, and MCR-1.  Identification of resistance to colistin, a last resort 
drug, within APEC has further exemplified the need to reduce the prevalence of this gene 
reservoir within poultry.  
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Alternatives to Antibiotics 
 With the rise of antibiotic resistance in microbial pathogens, there has been a surge in 
research to identify drugs or natural compounds that can prevent and reduce disease 
development in both animals and humans.  Recent identification of the involvement of the 
gut microbiota in the regulation of host metabolic pathways (112) has led much of the 
research to focus on developing a prophylactic treatment that supports a healthy gut 
microbiome.  Many of these treatment options try to optimize growth and development of 
beneficial bacteria and compounds that are already present in a healthy GI tract.  Three 
categories of prophylactic treatments that have been developed are prebiotics, probiotics, and 
postbiotics. 
Prebiotics are classified as non-digestible food ingredients that improve the health of 
the host through the promotion of growth or activity of beneficial bacteria present in the 
colon (113).  Prebiotics are typically defined by the presence of β-linkages in the cell wall 
that enable the prebiotic to survive the enzymatic degradation process of the upper GI tract 
(114).  In general, any indigestible fiber can be classified as a prebiotic, but only two 
prebiotics thus far meet all the criteria.  Inulins and fructooligosaccharides (FOS) are 
fermented by certain species and strains of lactic acid bacteria and Bifidobacterium, 
promoting the growth of these bacterial species and increasing the production of short chain 
fatty acids (SCFAs) (113, 114).  Specifically, fermentation of inulin results in the production 
of butyrate and fermentation of FOS produces acetate and lactic acid.  Colonocytes in the 
cecum and large intestine utilize the SCFAs for energy, with butyrate being the most 
important in this instance (115).  Additionally, SCFAs contribute to maintaining luminal pH 
acidity, modulating hormone secretion, activating fatty acid oxidation, regulating lipid and 
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glucose metabolism, and participating in anti-inflammatory processes (115, 116).  It has also 
been determined that butyrate is capable of downregulating genes in the Salmonella 
pathogenicity island (117), reducing the potential virulence of Salmonella species.  This is 
one indication of the importance of butyrate in the GI tract. 
Probiotics are live microorganisms added to feed or ingested in a capsule with the 
intention of promoting the health of the GI tract and the host as a whole (118).  The primary 
genus used in probiotics currently is Lactobacillus due to their association with a healthy GI 
tract (119).  Lactobacillus spp. contribute to a healthy GI tract via reduction of intestinal 
permeability and the reduction of pathogenic bacteria due to lactic acid, bacteriocins, and 
hydrogen peroxide production and competitive exclusion.  Probiotics are available for both 
human and animal use; however, inconsistent results indicate probiotics may need to be more 
specialized for animal species and their overall efficacy is debated (119).  In fact, a recent 
study determined that probiotics can have negative effects, inducing local inflammation in 
healthy hosts and in hosts with inflammatory bowel disease detrimentally effecting the 
inflamed tissue (120).  Results from this same study revealed that in a tissue model 
postbiotics are more effective at reducing inflammation caused by Salmonella than 
probiotics.  
Postbiotics are soluble metabolites produced by probiotic microorganisms that have 
been shown to have beneficial effects on the health of the GI tract, including bacteriocin 
effects, improvement of the integrity of the mucosal gut barrier, and modulation of 
inflammatory mediator secretion (121).  The most common postbiotics studied thus far have 
been metabolites derived from Lactobacillus species, with similar results seen across 
numerous animal species including rats, broiler chickens, laying hens, and swine (122–125).  
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Metabolites are most commonly included in the feed of the animal, and studies have 
determined they are most effective when a variety of metabolites isolated from different 
strains of Lactobacillus plantarum are included (123, 124).  Common benefits from the 
ingestion of these metabolites include a decrease in fecal pH, decrease in prevalence of 
Enterobacteriaceae in the feces contrasted with an increase in lactic acid bacteria, increase in 
the concentration of SCFAs present in the feces, and an increase in the height of the intestinal 
villi (122–125).  In piglets, these factors contributed to an overall increase in growth 
performance, indicated by birth weight, overall weight gain, average weight gain per day, 
and reduction in diarrhea production (124).  A similar study in laying hens found that 
postbiotics contributed to a reduction in plasma and yolk cholesterol within eggs (122).  This 
is an important benefit to humans that consume chicken eggs because cholesterol is known to 
be a leading cause of coronary heart disease (126).  Overall the numerous health benefits that 
have been identified from the use of postbiotics classifies them as favorable alternatives to 
antibiotics, with further research being done to identify additional benefits as well as other 
organisms that can provide beneficial metabolites. 
Recent research has focused on Saccharomyces cerevisiae fermentation products as a 
promoter for health in humans and animals.  Currently there are two yeast fermentation-
based products at the top of the market; EpiCor® (EpiCor) produced by Embria Health 
Services as a supplement for humans and Original XPCTM (XPC) produced by Diamond V as 
a feed additive for animals.  These postbiotics are a result of anaerobic fermentation of S. 
cerevisiae in a proprietary medium, followed by drying of the liquid in order to obtain the 
yeast metabolites (127).  Numerous studies have tested the efficacy of these products on the 
gut microbiota, host immune response, and growth response in production animals.  In vitro 
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studies indicate that XPC-adapted chicken ceca are better able to inhibit Salmonella 
colonization and result in increased concentrations of acetate and butyrate present (128). 
EpiCor studies have shown similar results, in addition to antioxidant and anti-inflammatory 
activity in human leukocytes (127, 129).   
In vivo studies have been vital in testing the efficacy of XPC, especially in production 
animals, the setting in which it has the potential to make a large impact in the replacement of 
antibiotics as growth additives.  Broiler chickens fed XPC in their diet exhibit a significant 
reduction in shedding and large intestinal colonization of Salmonella Typhimurium, as well 
as a reduction in tissue culture invasiveness and chloramphenicol resistance of the 
Salmonella colonies isolated from those chickens (130).  Weaned pigs have an overall 
improvement of growth performance, potentially due to the increased jejunal villi width and 
area allowing for enhanced digestion and absorption of nutrients in the intestine (131).  When 
the sows are fed XPC during gestation and lactation they produce litters with greater weight 
and require fewer recovery days between weaning and the next breeding cycle (132).  In 
Salmonella challenged pre-weaned dairy calves provided XPC in milk replacer and feed, 
there was a reduction in diarrhea and fever as well as improved development of the rumen 
(133).  The current research clearly indicates the benefits Saccharomyces cerevisiae 
fermentation products have on animal health, with further research still being done to test the 
effects on other gastrointestinal pathogens and antibiotic resistance across multiple species. 
Conclusion 
 Bacterial diseases such as urinary tract infections, neonatal meningitis, and avian 
colibacillosis are most commonly caused by ExPEC pathotypes.  These pathogens are well 
defined by the presence of a ColV or ColBM plasmid that harbors a large majority of the 
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core virulence genes.  The high transfer and recombination rate of these virulence and 
resistance plasmids has led ExPEC pathotypes to become a global public health concern.  
The potential of APEC as a zoonotic pathogen is exemplified by the new virulent Salmonella 
strain due to acquisition of ColV plasmid-encoded genes (70, 71) and a ColBM plasmid 
encoding macrolide resistance (47).  Additionally, APEC strains can cause both urinary tract 
infections and meningitis in rat models when inoculated in the appropriate location for 
disease to occur (23, 27).  It is therefore possible that APEC strains colonizing the poultry GI 
tract (134) could be consumed by humans and potentially cause human infections.  Even if 
APEC consumed from poultry does not result in disease, cells that survive the passage to the 
intestine will have the opportunity to transmit and recombine plasmids, potentially leading to 
the development of pathogenic organisms that were once commensal or more virulent and/or 
drug resistant APEC strains. 
 Given the potential APEC has as a zoonotic pathogen to humans and the large 
economic impact it has on the poultry industry, it is important to find a method of reducing 
its prevalence within poultry.  The increase in antibiotic resistance is leading to a reduction in 
the use of antibiotics as a disease preventative and growth promoter in feed animals.  
Original XPCTM is a postbiotic that is currently widely used and already has many proven 
benefits across multiple animal species (128, 130–132).  The fermented Saccharomyces 
cerevisiae product is produced by Diamond V and is provided to animals as a feed additive.  
Proven benefits within poultry include increased body weight, increased daily weight gain, 
reduction in both Salmonella Typhimurium and Campylobacter coli, and a decrease in 
Salmonella virulence and antibiotic resistance (130, 135).  Research should be done to 
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evaluate the efficacy on APEC prevalence and antibiotic resistance, to determine if XPC is a 
good alternative to antibiotics for the poultry industry. 
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CHAPTER 3: PREVALENCE OF AVIAN PATHOGENIC ESCHERICHIA COLI 
AND ANTIBIOTIC RESISTANCE OF E. COLI ISOLATES FROM THE CECA OF 
POULTRY FED ORIGINAL XPCTM 
 
Abstract 
 Avian pathogenic Escherichia coli (APEC), is an extra-intestinal pathogenic E. coli 
(ExPEC) pathotype.  It is the leading cause of avian colibacillosis and results in significant 
economic loss to the poultry industry annually.  While APEC is not a proven cause of disease 
in humans, it does transmit its plasmid-encoded virulence and resistance genes to 
Enterobacterieaceae.  Horizontal gene transfer is well known for resulting in increased 
antibiotic resistance and pathogenic conversion of commensal microorganisms.  Increased 
regulation of antibiotics as growth promoters and disease preventatives creates a void for 
antibiotic alternatives.  Original XPCTM (Diamond V, Cedar Rapids) is a Saccharomyces 
cerevisiae fermentation product originally used as a growth promoter.  Evidence has emerged 
indicating significant potential for the reduction of the prevalence of multiple pathogens.  To 
evaluate the effect of XPC on APEC, ceca from broiler poultry on XPC containing diets 
(treatment) or standard industry corn-soy based meal (control) were evaluated for changes in 
antibiotic resistance and the APEC pathotype.  Treatment with XPC resulted in a reduction in 
the prevalence of APEC by 50% in 10/13 of the poultry sources tested.  Antibiotic resistance 
in XPC-treated poultry exhibited an almost 2-fold reduction for ceftiofur, enrofloxacin, and 
chloramphenicol.  These results, combined with the results of previous studies, support XPC 
as a useful alternative antibiotic in the poultry industry. 
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Introduction 
 Avian pathogenic Escherichia coli (APEC) is a pathotype of extra-intestinal 
pathogenic E. coli (ExPEC), which are the cause of neonatal meningitis and urinary tract 
infections in humans (1).  The avian pathotype is the causative agent of colibacillosis and 
septicemia in birds that leads to localized inflammation, most commonly presenting as 
perihepatitis, airsacculitis, and/or pericarditis.  It can also be fatal.  Importantly, APEC 
colonizes the gastrointestinal tract of poultry, and accordingly is an opportunistic pathogen 
capable of causing disease in immunosuppressive states (2).  APEC is easily aerosolized 
from feces and thus threatens poultry housed together (1).  Further, APEC is inherently 
resistant to many common disinfectants, making management difficult (3).  This results in 
significant morbidity and mortality rates up to 20% and millions of dollars lost in the 
industry worldwide (4, 5), requiring a pressing need to find a management solution. 
 In addition to the impact on the poultry industry, APEC also has potential as a 
zoonotic pathogen due its shared set of virulence genes with human ExPEC pathotypes, 
uropathogenic E. coli (UPEC) and neonatal meningitis E. coli (NMEC) (6–8).  The pathotype 
UPEC is one of the leading causative agents of urinary tract infections (9) and NMEC the 
second leading cause of neonatal meningitis worldwide (10).  Interestingly, APEC strains can 
cause urinary tract infections and meningitis in rat models, and UPEC and NMEC strains can 
cause colibacillosis in poultry (11, 12).  These studies suggest that APEC inadvertently 
transferred from poultry has the potential to cause disease in humans.  Further, due to the 
nature of Enterobacteriaceae, APEC acts as a reservoir of virulence and antimicrobial 
resistance genes that are easily transferrable to other E. coli strains or Gram-negative species 
residing in the microbiota.  Previous studies have revealed that acquisition of a pColV by 
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commensal E. coli results in the ability of the organism to cause lethality in chicken embryos, 
enhanced in vitro growth in human urine, and colonization of the kidney in a murine model 
(13). 
 A colicin plasmid, pColV, contains a majority of the core virulence genes that are 
characteristic of ExPEC pathogenesis (14).  With the common occurrence of recombination 
among plasmids and bacterial chromosomes (15), these virulence genes have the potential to 
be transferred to not only other E. coli but also other bacterial species.  This is exemplified in 
the identification of ColV plasmid-linked virulence genes in a strain of Salmonella enterica 
serovar Kentucky that increase colonization capabilities of the pathogen and increase 
virulence in extra-intestinal regions of the poultry (16).   
A concerning feature of APEC resides in the antimicrobial resistance genes associated 
with non-colicin and colicin plasmids (17).  Plasmid mediated antibiotic resistance within 
ExPEC isolates thus far include ESBL carriage, including CTX-M (18, 19), NDM-1 (20, 21), 
as well as MCR-1 (22).  Enterobacteriaceae serves as a potent reservoir for these plasmids 
and enhances the concern of the spread of antimicrobial resistance.  This rise of antibiotic 
resistance in not only ExPEC but many other human and animal pathogens has forced an 
evaluation of the use of antibiotics, especially within food animal production (23).  
Antibiotics are commonly used for growth promotion and disease prophylaxis.  The void left 
requires immediate investigation into potent alternatives to antibiotics that act as both 
efficacious prophylaxis and growth promoters. 
 Yeast fermentation products from Saccharomyces cerevisiae have recently been at the 
forefront of this research endeavor due to largely efficacious results across multiple food 
animals.  The benefits include reduction of pathogenic bacteria, modification of intestinal 
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morphology to improve nutrient absorption, enhancement of the immune system, and 
reduction of energy required for intestinal epithelial maintenance (24–27).  The fermentation 
of the yeast produces beneficial metabolites while reducing the potentially negative effects of 
live cultures.  These metabolites produced include carotenoids, vitamins, enzymes, amino 
acids, and some yet uncharacterized products that appear to be beneficial to host health.  
Original XPCTM (Diamond V, Cedar Rapids), has emerged as a relevant postbiotic.  The 
evaluation of the efficacy of XPC in poultry revealed an increase in finisher weight, decrease 
in feed to gain ratios, a reduction in Salmonella Typhimurium and Campylobacter coli 
colonization and shedding, and a decrease in Salmonella virulence and antibiotic resistance 
(24, 25, 28).  Given that Salmonella enterica and E. coli are genetically at least 95% similar 
(29), it is reasonable to hypothesize that XPC might have similar effects on APEC within 
poultry.  
 Currently the best method available for identifying APEC is the pentaplex PCR assay 
designed by Johnson et al (4).  For E. coli to be classified as APEC, all 5 ColV plasmid-
associated virulence genes must be present: iroN, ompT, hlyF, iss, and iutA.  Respectively, 
these genes encode a salmochelin siderophore receptor (iroN) (30), a putative outer 
membrane protein (ompT) (31), a protein involved in outer membrane vesicle formation 
(hlyF) (32), a polypeptide that increases serum survival (iss) (33), and an aerobactin 
siderophore receptor (iutA) (34).   
It is currently unknown as to if XPC decreases APEC virulence and colonization in 
poultry.  To evaluate changes in APEC carriage, the pentaplex PCR assay was performed on 
E. coli cultured from the ceca of broiler chickens and turkeys from thirteen poultry factories 
across the United States.  Additionally, antibiotic resistance was evaluated using an 
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antibiogram on individual E. coli isolates from poultry ceca.  Results indicate an overall 
reduction in the prevalence of APEC in poultry fed an XPC-based diet compared to those on 
a standard diet. 
Materials and Methods 
Study Design 
Ceca were collected on site from poultry headed to slaughter from thirteen different 
poultry sources across the United States; 5 sources provided turkey ceca, 7 sources provided 
broiler chicken ceca, and 1 source provided cloacal swabs from layer chickens.  At each 
source, birds were fed either an XPC containing diet (treatment) or standard industry corn-
soy based meal (control).  Over a 15-month period ceca were shipped overnight and received 
in Whirl-Pak® bags on ice in groups of 25-100, each group representing a poultry barn fed 
either the XPC-based diet or the control diet.  At the time of the study all lab employees 
remained uninformed to the classification of the barns.   
E. coli Isolation 
 To evaluate the colonization of poultry with APEC, turkey or chicken ceca were 
weighed, ligated, and contents were resuspended in Luria Broth (LB).  The contents were 
massaged to release the cecal contents and aliquoted onto Xylose Lysine Deoxycholate 
(XLD) agar, a selective and differential medium for the isolation of Enterobacteriaceae and 
Pseudomonas.  The inoculated XLD plates were then incubated at 35⁰C for 24 hours. 
Following incubation, 9-10 XLD plates were selected from each barn as a 
representative sample.  Plates were selected based on the presence of individual E. coli 
colonies, appearing on XLD agar as round, white colonies on yellow medium due to 
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fermentation of the lactose and xylose.  For each plate, 100 E. coli colonies were collected 
into 1 mL of sterile LB using sterile toothpicks and vortexed.  The E. coli suspensions were 
stored at 4⁰C and processed within 7 days. 
Colony Pentaplex PCR Assay 
 To identify the presence of APEC within each cecum, the E. coli suspension was 
subjected to a pentaplex PCR assay, modified from Johnson et al (4).  Primers are identified 
with the expected amplicon sizes in Table 1.  The protocol was modified with the following 
procedure.  The Q5 High-Fidelity PCR kit from New England BioSciences was utilized for 
this study.  Master mix was created per reaction that included 10.4 µL DEPC, 4 µL Q5® α 
Enhancing buffer, 4 µL Q5® α Enhancer, 0.4 µL dNTP (10µM), 0.2 µL Q5® α polymerase, 
5 pM of each primer (100 µM; totaling 0.5 µL per reaction), and 0.5 µL of template.  
Template was created by boiling 50 µL of the E. coli suspension for 20 minutes.  The 
template was diluted 1:2 with DEPC prior to addition to the master mix.  The PCR cycling 
was optimized for the Q5 High-Fidelity PCR kit: 98⁰C for 30 seconds followed by 35 cycles 
of 98⁰C for 10 seconds, 67⁰C for 30 seconds, 72⁰C for 15 seconds, and then 72⁰C for 5 
minutes for terminal extension.  The completed PCR product was subjected to 2% agarose 
gel electrophoresis at 120 mV and visualized under an ultraviolet light.  Samples were 
considered positive for APEC only if all 5 bands were visualized on the gel.  Positive and 
negative APEC controls were utilized.  The positive APEC control was grown at 37⁰C, 
subject to colony PCR, purified using the Zymo Research DNA Clean & ConcentratorTM -5 
Kit, and stored at -20⁰C until use due to the instability of the plasmid. 
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Antibiogram 
 From the same barn, 24 XLD plates were selected for the antibiotic resistance assay.  
Isolates were collected into a 96-well round bottom polystyrene plate filled with 300 µL of 
LB.  From each plate, 2 E. coli colonies were selected individually using a sterile toothpick 
and each colony was placed in its own individual well.  The 96-well plate was incubated at 
37⁰C for 18-24 hours and then subjected to pin-replicating into 3 separate 96-well plates 
containing a different antibiotic media at their respective, predetermined breakpoint 
concentrations.  Antibiotics selected for this assay are ceftiofur (32 ug/mL), enrofloxacin (8 
ug/mL), and chloramphenicol (32 ug/mL).  Following incubation, the wells were visually 
analyzed for growth, with any turbidity or breading of colonies considered a positive result. 
Statistics 
 Significance of control versus XPC-treated birds within each source was performed 
for both prevalence and antibiotic resistance data using a 2-way ANOVA with repeated 
measures with Tukey’s multi-comparison test. 
Results 
Colony Pentaplex PCR Assay 
 Thirteen poultry sources were subjected to the APEC survey with approximately 
2,000 turkeys and 3,000 chickens tested.  All 13 of the poultry sources exhibited a reduction 
in prevalence of APEC in poultry fed an XPC-based diet (Table 2).  Within the control 
groups of turkeys, the prevalence of APEC positive colonies ranged from 44% to 100%, 
while in the XPC-treated groups the prevalence ranged from 16% to 50% (Figure 1).  Within 
chickens, the prevalence of APEC positive colonies in control groups ranged from 60% to 
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93% and in treatment groups ranged from 25% to 50% (Figure 2).  The two sources 
identified as having a non-statistically significant difference in prevalence were C3 and C7.  
Three sources were identified with a p < 0.001 (T4, C2, and C4), four with a p < 0.005 (T2, 
T3, C1, and L1), one with a p < 0.01 (C6), and three with a p < 0.05 (T1, T5, and C5). 
Antibiogram 
In this study, E. coli colonies collected from poultry ceca were tested for resistance 
against ceftiofur, enrofloxacin, and chloramphenicol.  Ceftiofur was the initial antibiotic 
tested with results indicating a statistically significant reduction of resistant E. coli colonies 
in poultry fed an XPC-based diet in 11 of the 13 poultry sources (Table 3).  The portion of 
resistant colonies in the control group of turkeys ranged from 55% to 91%, while the XPC-
fed group ranged from 30% to 48% (Figure 3A).  Chickens from the control group had 
resistance colonies ranging from 38% to 100% and the treatment group ranging from 17% to 
48% (Figure 4A).  Most of the poultry sources exhibited a significant p-value less than 0.001, 
the exception being source C1 with a p < 0.01 and T4 and L1, which were not statistically 
significant. 
 Enrofloxacin and chloramphenicol resistance assays were included after initial 
ceftiofur data indicated a reduction in the XPC-fed group.  For this reason, enrofloxacin and 
chloramphenicol resistance data is not included for sources C1-C4.  Additionally, no control 
group resistance data was recorded for these two antibiotics for source T1.  Antibiogram data 
for enrofloxacin revealed 5 of the 8 barns exhibited a statistically significant reduction in 
resistance (Table 3).  Enrofloxacin resistance for turkeys ranged from 30% to 72% in the 
control group and from 17% to 44% in the XPC-fed group (Figure 3B).  Chickens exhibited 
enrofloxacin resistance ranging from 34% to 73% in the control group and 10% to 23% in the 
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treatment group (Figure 4B).  Sources T2, T3, T5, C5, and C6 had a p-value < 0.001.  Of the 
8 poultry sources tested for chloramphenicol resistance, all exhibited a statistically significant 
reduction in chloramphenicol resistant colonies.  Chloramphenicol resistance in turkeys 
ranged from 58% to 99% in the control group and from 20% to 51% in the XPC-fed group 
(Figure 3C).  Chickens in control groups exhibited a resistance range of 85% to 96% and in 
treatment groups a range of 22% to 52% (Figure 4C).  All 8 sources exhibited a significant 
difference indicated by a p-value < 0.001. 
Discussion 
 Diamond V Original XPCTM is a Saccharomyces cerevisiae fermentation product 
added to feed that has proved quite successful in increasing growth weight of animals and 
decreasing intestinal colonization of pathogens (24–26, 28).  Given the success of XPC in 
reducing Salmonella Typhimurium and Campylobacter coli colonization in poultry (24, 25, 
28), this study looked at the effects of XPC on APEC colonization in poultry.  
Eleven of the 13 poultry sources tested exhibited a statistically significant reduction in 
the amount of APEC isolated from the ceca of poultry fed a diet with XPC added.  Evidence 
is highly suggestive of a role the microbiota plays in the reduction of food animal pathogens.  
Consumption of XPC lowers the intestinal pH which may reduce the success of E. coli 
colonization (35, 36).  Likely this occurs because at a lower pH short chain fatty acids such 
as propionic acid and formic acid can reduce an E. coli population by 90% without damaging 
the cell membrane (37).  Further, intestinal butyrate increases in animals fed XPC containing 
products (38).  Butyrate is used by enterocytes as a primary energy source and increases the 
growth of Lactobacillus spp. while decreasing Enterobacteriaceae growth (39).  In vitro, 
XPC has been shown to reduce gastrointestinal inflammation (40) and increase microbial 
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competition and diversity through modulations in the availability of SCFAs (38).  This 
competitive enhancement strategy supports the growth of organisms that can act as a natural 
competitive exclusion culture against pathogens in the gastrointestinal tract (41).  Our study 
also revealed that poultry fed an XPC-based diet demonstrate a significant reduction in the 
number of E. coli cells resistant to ceftiofur, enrofloxacin, and chloramphenicol, further 
supporting the usefulness of XPC as a good alternative to antibiotics in poultry.  This 
evidence parallels what is seen in Salmonella recovered from XPC fed animals (25).   
In summary, this survey provides substantial evidence for the use of Original XPCTM 
to help reduce the amount of APEC as well as the number of antibiotic resistant 
microorganisms in the microbiota of chickens and turkeys.  Combining these results with the 
results of other studies, indicates that overall XPC appears to be an alternative to antibiotics 
in feed for growth promotion and the prevention of diseases.  Future work should be 
considered to elucidate the components of XPC that are acting on APEC to reduce 
prevalence in the gastrointestinal tract and what mechanisms result in a reduction of 
antibiotic resistance.  
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Figure 1. Prevalence of APEC in ceca of ~2,000 turkeys (T) from 5 different sources in 
the United State. Birds were fed a diet with (XPC) or without (control) Diamond V 
Original XPCTM. p-values calculated from a 2-way ANOVA with repeated measures 
with Tukey’s multi-comparison test: p < 0.05 (*), p < 0.005 (***), p < 0.001 (****). 
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Figure 2. Prevalence of APEC in ceca of ~3,000 broiler chickens (C) and layers (L) from 
8 different sources in the United State. Birds were fed a diet with (XPC) or without 
(control) Diamond V Original XPCTM. p-values calculated from a 2-way ANOVA with 
repeated measures with Tukey’s multi-comparison test: p < 0.05 (*), p < 0.001 (**), p < 
0.005 (***), p < 0.001 (****). 
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Figure 3. Ceftiofur (A), enrofloxacin (B), and chloramphenicol (C) resistance 
rates of E. coli colonies isolated from the ceca of ~ 2,000 turkeys (T) from 5 
sources across the United States.  Data collection for source T1 was incomplete 
for Enrofloxacin and Chloramphenicol resistance. Birds were fed a diet with 
(XPC) or without (control) Diamond V Original XPCTM. p-value calculated from 
a 2-way ANOVA with repeated measures with Tukey’s multi-comparison test: p 
< 0.001 (****). 
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Figure 4. Ceftiofur (A), enrofloxacin (B), and chloramphenicol (C) resistance 
rates of E. coli colonies isolated from the ceca of ~3,000 broiler chickens (C) and 
layers (L) from 8 sources across the United States. Data collection for source C1-
C4 was incomplete for Enrofloxacin and Chloramphenicol resistance. Birds were 
fed a diet with (XPC) or without (control) Diamond V Original XPCTM. p-value 
calculated from a 2-way ANOVA with repeated measures with Tukey’s multi-
comparison test: p < 0.01 (**), p < 0.001 (****). 
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CHAPTER 4: GENERAL CONCLUSIONS 
 
 With the advent of further antibiotic usage restrictions in the Veterinary Feed 
Directive and the rising concern of APEC as a zoonotic pathogen, research identifying 
regulatory methods for APEC in poultry is critical.  Demonstration of the public health 
concern of APEC was exemplified by the increase in antibiotic resistance and high 
transmission of virulence plasmids.  A combined concern for poultry and human health led to 
a desire to identify a prophylactic treatment for APEC to mitigate disease in poultry and the 
propagation of the pathogen via food sources.  The survey presented in this thesis 
successfully analyzed poultry from sources across the United States for APEC prevalence 
and E. coli antibiotic resistance.  Results revealed that Original XPCTM is efficacious in 
reducing poultry carriage of APEC and reducing the presence of E. coli resistant to ceftiofur, 
enrofloxacin, and chloramphenicol.  Identification of a prophylactic treatment for APEC is 
economically beneficial for the poultry industry and will potentially reduce the threat to 
public health. 
Since this was a surveillance study, much more work needs to be done to elucidate 
the mechanisms of action of XPC.  Initial studies should be done to determine if there is a 
reduction in virulence, identified by the loss of function of any of the important virulence 
genes.  Genetic regulation of the virulence or resistance genes by a component of XPC or the 
gut microbiota could be a point of mechanistic action.  Additionally, further studies should be 
done evaluating the effects of XPC on the overall gut microbiota, including but not limited to 
community sequencing and calculating concentration changes of metabolites in the GI tract.  
Finally, additional surveillance studies should be done testing the efficacy of XPC on other 
Enterobacteriaceae pathogens and viruses across numerous animal species. 
